Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Note 3 - Revenue 1 (Tables)

Note 3 - Revenue 1 (Tables) - Pieris Pharmaceuticals, Inc. [Member]

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Notes Tables

Disaggregation of Revenue [Table Text Block]

		*Three Months Ended September 30,*								*Nine Months Ended September 30,*
		*2024*				*2023*				*2024*				*2023*
Pfizer (formerly Seagen)		$	—			$	9,179			$	6			$	14,088
AstraZeneca			—				3,909				—				8,399
Servier			—				3,951				47				3,846
Genentech			—				—				—				12,697
Boston Pharmaceuticals			—				2,481				—				2,481
Total Revenue		$	—			$	19,520			$	53			$	41,511

		Year Ended December 31,
		2023				2022
AstraZeneca		$	8,399			$	9,117
Pfizer			15,134				8,287
Servier			4,099				5,359
Genentech			12,697				3,139
Boston Pharmaceuticals			2,481				—
Total Revenue		$	42,810			$	25,902

Revenue From Contract With Customer, Milestone Payments [Table Text Block]

		*Research, Development, Regulatory & Commercial Milestones*				*Sales Milestones*
Pfizer (formerly Seagen)		$	759			$	450
Boston Pharmaceuticals			85				265
Total potential milestone payments		$	844			$	715

		Research, Development, Regulatory & Commercial Milestones				Sales Milestones
Pfizer		$	759			$	450
Servier			107				99
Boston Pharmaceuticals			85				265
Total potential milestone payments		$	951			$	814